Leerink Partners Reiterates Buy Rating on NovoCure Limited with $33 Price Target

Leerink Partners analyst Jonathan Chang has reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR), setting a price target of $33.00. The company reported solid Q2 2025 results, exceeding revenue expectations with $158.8 million, driven by a rise in active patient numbers. Chang also noted growth in prescriptions and active patients for Optune Lua in non-small cell lung cancer, suggesting potential for future growth.

Leerink Partners analyst Jonathan Chang has reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR), setting a price target of $33.00. The company reported solid Q2 2025 results, exceeding revenue expectations with $158.8 million, driven by a rise in active patient numbers. Chang also noted growth in prescriptions and active patients for Optune Lua in non-small cell lung cancer, suggesting potential for future growth.

NovoCure Limited develops, manufactures, and commercializes Optune, a platform called Tumor Treating Field that employs electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company's strong Q2 performance was attributed to increased demand for its products, with a notable rise in active patient numbers across major markets.

Chang highlighted the company's ongoing efforts to expand its market reach and indicated that the potential for future growth in non-small cell lung cancer is promising. However, he also acknowledged that certain AI stocks may offer greater upside potential and carry less downside risk. For investors looking for undervalued AI stocks with significant upside potential, Chang suggested exploring other opportunities.

References:
[1] https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/is-novocures-nvcr-rising-active-patient-count-reshaping-its
[2] https://finance.yahoo.com/news/leerink-partners-reiterates-buy-rating-160832900.html
[3] https://ca.finance.yahoo.com/news/leerink-partners-reiterates-buy-rating-160832900.html